Trial Profile
A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Dec 2021
Price :
$35
*
At a glance
- Drugs Pamiparib (Primary) ; Tislelizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Carcinoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Gynaecological cancer; HER2 negative breast cancer; Nerve sheath neoplasms; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors BeiGene
- 22 Sep 2020 Status changed from active, no longer recruiting to completed.
- 20 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 26 Feb 2020 Planned End Date changed from 1 Apr 2020 to 15 Sep 2020.